Gold Investment Management Ltd. Acquires 279 Shares of Johnson & Johnson $JNJ

Gold Investment Management Ltd. raised its holdings in Johnson & Johnson (NYSE:JNJ) by 1.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,790 shares of the company’s stock after buying an additional 279 shares during the quarter. Gold Investment Management Ltd.’s holdings in Johnson & Johnson were worth $2,914,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Brighton Jones LLC boosted its stake in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Matrix Trust Co boosted its stake in shares of Johnson & Johnson by 17.5% in the 1st quarter. Matrix Trust Co now owns 982 shares of the company’s stock valued at $163,000 after purchasing an additional 146 shares in the last quarter. Wealth Group Ltd. acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at $218,000. Vest Financial LLC boosted its stake in shares of Johnson & Johnson by 10.7% in the 1st quarter. Vest Financial LLC now owns 405,364 shares of the company’s stock valued at $67,226,000 after purchasing an additional 39,217 shares in the last quarter. Finally, AMI Investment Management Inc. boosted its stake in shares of Johnson & Johnson by 3.3% in the 1st quarter. AMI Investment Management Inc. now owns 26,344 shares of the company’s stock valued at $4,369,000 after purchasing an additional 852 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $188.51 on Friday. The stock has a market capitalization of $453.98 billion, a P/E ratio of 20.16, a P/E/G ratio of 2.37 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $189.78. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The business has a 50-day moving average price of $176.18 and a two-hundred day moving average price of $162.83.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

Analyst Ratings Changes

Several equities research analysts have recently commented on JNJ shares. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Barclays upped their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Citigroup upped their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a research report on Thursday, August 21st. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price target for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Finally, UBS Group set a $198.00 price target on shares of Johnson & Johnson in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $187.47.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.